AB124. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer

Objective Receptor for advanced glycation end products (RAGE), along with its ligand high mobility group box 1 (HMGB1), is believed to play an important role in prostate cancer. The aim of this retrospective study was to investigate the expression of RAGE and HMGB1 and their clinical impact on prostate cancer progression and prognosis.